



SUVEN Life Sciences Ltd

Communication to investors **December 2017**

30-Jan-18

2017-18 Q3 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



FINANCIAL QUICK VIEW

	FY 2017-18 Q3 to Q2	FY 2017-18 YoY 9 months
Growth in revenue	49.07%	11.85%
Growth in Pre-R&D EBIDTA	10.96%	10.19%
Growth in EBIDTA	9.08%	16.79%
Growth in PAT	8.99%	15.38%
R&D to sales	8.31%	9.76%
Increase in R&D Costs	19.01%	-9.08%

MAJOR PROFITABILITY RATIOS







	Q3 Dec 17	9 months- Dec 17
Pre-R&D EBITDA to Income	41.07%	46.35%
EBIDTA to Income	32.75%	36.59%
PAT to Income	20.71%	22.52%
Cash Flow to Income	23.97%	26.29%



Q3 to Q2 COMPARISON


Current quarter to previous quarter





REVENUE COMPARISON

Year on year




30-Jan-18

2017-18 Q3 results



PAT COMPARISON

Year on year




30-Jan-18

2017-18 Q3 results



EBIDTA COMPARISON

Year on year



30-Jan-18

2017-18 Q3 results



R & D – EXPENDITURE


Year on year





PRE-R&D EBIDTA

Year on year




30-Jan-18

2017-18 Q3 results



PRE-R&D CASHFLOW

Year on year



30-Jan-18

2017-18 Q3 results



FINANCIAL SNAPSHOT

All figures are in INR Million, other than ratios and EPS

	2017-18 Q3	2017-18 Q2	Growth %	2016-17 Q3	Growth %	2017-18 9 mons	2016-17 9 mons	Growth %
Income	1,669.47	1,119.91	49.07%	1,204.55	38.60%	4,255.80	3,804.84	11.85%
Pre-R&D EBITDA	685.59	617.89	10.96%	581.24	17.95%	1,972.70	1,790.35	10.19%
Pre-R&D EBITDA Margin	41.07%	55.17%		48.25%		46.35%	47.05%	
EBITDA	546.81	501.28	9.08%	417.64	30.93%	1,557.19	1,333.31	16.79%
EBITDA Margin	32.75%	44.76%		34.67%		36.59%	35.04%	
EBIT	492.64	447.88	10.00%	368.92	33.54%	1,397.70	1,191.01	17.35%
EBIT Margin	29.51%	39.99%		30.63%		32.84%	31.30%	
Financing costs	11.52	9.36		12.65		33.58	40.98	
Taxes	135.15	121.05		113.57		404.96	316.00	
Net Profit after tax	345.74	317.23	8.99%	241.58	43.12%	958.43	830.65	15.38%
NP Margin	20.71%	28.33%		20.06%		22.52%	21.83%	
EPS (basic & diluted not annualised)	2.72	2.49		1.90		7.53	6.53	
Paid up share capital (One Rupee Share)	127.28	127.28		127.28		127.28	127.28	
Depreciation	54.17	53.40		48.72		159.49	142.30	
R&D expenses	138.78	116.61	19.01%	163.60	-15.17%	415.52	457.03	-9.08%

30-Jan-18

2017-18 Q3 results

News Release



- During the period Suven secures 9 product patents covering Canada, India, Eurasia, Hong Kong, Norway and USA
- Suven participated in Neuroscience 2017, held in November in Washington DC, USA
- Suven participated in AAPS, held in November 2017 in San Diego, USA
- Suven presented in B&K Investor Conference - Emergent India in December 2017
- The Board has proposed an Interim Dividend of Re. 1.50 per share (150% of face value of Rs. 1.00 each).